V3V Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Storage BusinessVita 34’s core offering is long-term cryogenic storage with end-to-end logistics, testing and secure infrastructure. That model generates highly recurring, contract-driven revenues with strong customer stickiness and high switching costs, supporting predictable long-term cash inflows and lifetime customer value.
Margin ImprovementSubstantial gross margin expansion and a positive EBITDA margin indicate improved pricing, process efficiency or mix shift. Higher margins help absorb fixed costs, improve operating leverage as volumes recover, and create a clearer path to sustainable profitability even if top-line growth is uneven.
Positive Operating Cash FlowPositive operating cash flow despite accounting losses shows the core business generates cash. That reduces immediate liquidity stress, helps service short-term obligations, and provides a base to fund incremental investments or restructuring without relying wholly on external financing.
Bears Say
Sharp Revenue DeclineA dramatic 67% TTM revenue drop materially reduces scale economics and undermines fixed-cost absorption. Sustained declines can erode customer acquisition returns, weaken market positioning, and prolong the timeline to restore profitable growth even if margins per unit have improved.
Elevated LeverageHigh leverage relative to a small equity base constrains financial flexibility and increases refinancing and interest-rate risk. With limited capital cushions, the company faces higher default risk or covenant pressure if cash flow deteriorates, reducing capacity for growth investments or strategic moves.
Negative Profitability / ROEPersistent net losses and deeply negative ROE erode shareholder equity and signal weak earnings power. This hinders ability to raise equity on favorable terms, limits reinvestment, and makes sustained recovery dependent on either structural revenue rebound or significant margin improvement being sustained over multiple periods.
V3V FAQ
What was VITA 34 AG’s price range in the past 12 months?
Currently, no data Available
What is VITA 34 AG’s market cap?
VITA 34 AG’s market cap is CHF48.27M.
When is VITA 34 AG’s upcoming earnings report date?
VITA 34 AG’s upcoming earnings report date is Aug 28, 2026 which is in 29 days.
How were VITA 34 AG’s earnings last quarter?
Currently, no data Available
Is VITA 34 AG overvalued?
According to Wall Street analysts VITA 34 AG’s price is currently Undervalued.
Does VITA 34 AG pay dividends?
VITA 34 AG does not currently pay dividends.
What is VITA 34 AG’s EPS estimate?
VITA 34 AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VITA 34 AG have?
Currently, no data Available
What happened to VITA 34 AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VITA 34 AG?
Currently, no hedge funds are holding shares in CH:V3V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VITA 34 Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.87%
Trailing 12-Months
Company Description
VITA 34 AG
VITA 34 AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced therapeutic solutions, including cell and gene therapies, specialized cell therapeutic procedures, cryopreservation of a patient's own immune cells, and CAR-T cell technology. Furthermore, VITA 34 manufactures advanced therapy medicinal products (ATMPs) based on mesenchymal stem cells for experimental applications by specialized medical institutions. It also preserves stem cells from perinatal tissues and adult body fat, and provides contract manufacturing for pharmaceutical intermediates. Founded in 1997, VITA 34 AG is headquartered in Leipzig, Germany.